Cargando…
OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution
Effective therapeutics for ovarian cancer continue to be urgently needed, particularly for chemotherapy-resistant cases. Here we present both a 3D-Matrigel culture-based expansion of our directed evolution method for generation of oncolytic virotherapies and two promising ovarian-cancer targeted onc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363728/ https://www.ncbi.nlm.nih.gov/pubmed/28345024 http://dx.doi.org/10.1016/j.omto.2016.12.001 |
_version_ | 1782517205090435072 |
---|---|
author | Kuhn, Irene Bauzon, Maxine Green, Nicola Seymour, Len Fisher, Kerry Hermiston, Terry |
author_facet | Kuhn, Irene Bauzon, Maxine Green, Nicola Seymour, Len Fisher, Kerry Hermiston, Terry |
author_sort | Kuhn, Irene |
collection | PubMed |
description | Effective therapeutics for ovarian cancer continue to be urgently needed, particularly for chemotherapy-resistant cases. Here we present both a 3D-Matrigel culture-based expansion of our directed evolution method for generation of oncolytic virotherapies and two promising ovarian-cancer targeted oncolytic viruses, OvAd1 and OvAd2. OvAd1 was developed using Matrigel cell cultures, whereas OvAd2 was developed in parallel using traditional monolayer tissue culture methods. Both viruses are potent against a panel of platinum-resistant ovarian cancer cell lines and are attenuated on normal cells in vitro, resulting in therapeutic windows of ∼200-fold. We observed two benefits of the use of Matrigel-based cultures for directed evolution of these oncolytics: (1) use of Matrigel generated a bioselected pool that was more strongly attenuated on normal cells while retaining its potency against ovarian cancer cells, and (2) in an ovarian carcinomatosis model, the Matrigel-derived virus OvAd1 suppressed all tumor growth while the non-Matrigel-derived virus was 50% effective. Neither virus stimulated formation of peritoneal adhesions as seen for Ad5-based therapies. Consequently, these viruses are novel candidates for development as new effective treatments for aggressive ovarian cancer. |
format | Online Article Text |
id | pubmed-5363728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-53637282017-03-24 OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution Kuhn, Irene Bauzon, Maxine Green, Nicola Seymour, Len Fisher, Kerry Hermiston, Terry Mol Ther Oncolytics Original Article Effective therapeutics for ovarian cancer continue to be urgently needed, particularly for chemotherapy-resistant cases. Here we present both a 3D-Matrigel culture-based expansion of our directed evolution method for generation of oncolytic virotherapies and two promising ovarian-cancer targeted oncolytic viruses, OvAd1 and OvAd2. OvAd1 was developed using Matrigel cell cultures, whereas OvAd2 was developed in parallel using traditional monolayer tissue culture methods. Both viruses are potent against a panel of platinum-resistant ovarian cancer cell lines and are attenuated on normal cells in vitro, resulting in therapeutic windows of ∼200-fold. We observed two benefits of the use of Matrigel-based cultures for directed evolution of these oncolytics: (1) use of Matrigel generated a bioselected pool that was more strongly attenuated on normal cells while retaining its potency against ovarian cancer cells, and (2) in an ovarian carcinomatosis model, the Matrigel-derived virus OvAd1 suppressed all tumor growth while the non-Matrigel-derived virus was 50% effective. Neither virus stimulated formation of peritoneal adhesions as seen for Ad5-based therapies. Consequently, these viruses are novel candidates for development as new effective treatments for aggressive ovarian cancer. American Society of Gene & Cell Therapy 2016-12-14 /pmc/articles/PMC5363728/ /pubmed/28345024 http://dx.doi.org/10.1016/j.omto.2016.12.001 Text en © 2016 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Kuhn, Irene Bauzon, Maxine Green, Nicola Seymour, Len Fisher, Kerry Hermiston, Terry OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
title | OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
title_full | OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
title_fullStr | OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
title_full_unstemmed | OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
title_short | OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
title_sort | ovad1, a novel, potent, and selective chimeric oncolytic virus developed for ovarian cancer by 3d-directed evolution |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363728/ https://www.ncbi.nlm.nih.gov/pubmed/28345024 http://dx.doi.org/10.1016/j.omto.2016.12.001 |
work_keys_str_mv | AT kuhnirene ovad1anovelpotentandselectivechimericoncolyticvirusdevelopedforovariancancerby3ddirectedevolution AT bauzonmaxine ovad1anovelpotentandselectivechimericoncolyticvirusdevelopedforovariancancerby3ddirectedevolution AT greennicola ovad1anovelpotentandselectivechimericoncolyticvirusdevelopedforovariancancerby3ddirectedevolution AT seymourlen ovad1anovelpotentandselectivechimericoncolyticvirusdevelopedforovariancancerby3ddirectedevolution AT fisherkerry ovad1anovelpotentandselectivechimericoncolyticvirusdevelopedforovariancancerby3ddirectedevolution AT hermistonterry ovad1anovelpotentandselectivechimericoncolyticvirusdevelopedforovariancancerby3ddirectedevolution |